149 related articles for article (PubMed ID: 19619928)
1. Azole resistant Candida glabrata vulvovaginitis treated with boric acid.
Savini V; Catavitello C; Bianco A; Balbinot A; D'Antonio F; D'Antonio D
Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):112. PubMed ID: 19619928
[No Abstract] [Full Text] [Related]
2. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
3. Clinical resistance of recurrent Candida albicans vulvovaginitis to fluconazole in the presence and absence of in vitro resistance.
MacNeill C; Weisz J; Carey JC
J Reprod Med; 2003 Feb; 48(2):63-8. PubMed ID: 12621787
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis.
Ray D; Goswami R; Banerjee U; Dadhwal V; Goswami D; Mandal P; Sreenivas V; Kochupillai N
Diabetes Care; 2007 Feb; 30(2):312-7. PubMed ID: 17259500
[TBL] [Abstract][Full Text] [Related]
5. [In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples].
Hüseyin A; Sancak B; Arikan S
Mikrobiyol Bul; 2007 Apr; 41(2):235-44. PubMed ID: 17682710
[TBL] [Abstract][Full Text] [Related]
6. Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole.
Borst A; Raimer MT; Warnock DW; Morrison CJ; Arthington-Skaggs BA
Antimicrob Agents Chemother; 2005 Feb; 49(2):783-7. PubMed ID: 15673768
[TBL] [Abstract][Full Text] [Related]
7. Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies.
Vermitsky JP; Earhart KD; Smith WL; Homayouni R; Edlind TD; Rogers PD
Mol Microbiol; 2006 Aug; 61(3):704-22. PubMed ID: 16803598
[TBL] [Abstract][Full Text] [Related]
8. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species.
Sobel JD; Sobel R
Expert Opin Pharmacother; 2018 Jun; 19(9):971-977. PubMed ID: 29932786
[TBL] [Abstract][Full Text] [Related]
9. Lack of correlation of 24- vs. 48-h itraconazole minimum inhibitory concentrations with microbiological and survival outcomes in a guinea pig model of disseminated candidiasis.
Odabasi Z; Paetznick VL; Rodriguez JR; Chen E; Rex JH; Leitz GJ; Ostrosky-Zeichner L
Mycoses; 2010 Sep; 53(5):438-42. PubMed ID: 19500259
[TBL] [Abstract][Full Text] [Related]
10. Azole resistance of Candida glabrata in a case of recurrent fungemia.
Posteraro B; Tumbarello M; La Sorda M; Spanu T; Trecarichi EM; De Bernardis F; Scoppettuolo G; Sanguinetti M; Fadda G
J Clin Microbiol; 2006 Aug; 44(8):3046-7. PubMed ID: 16891541
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility of oral Candida to seven antifungal agents.
Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
[TBL] [Abstract][Full Text] [Related]
12. Candida glabrata complicating in vitro pregnancy: successful management of subsequent pregnancy.
Asemota OA; Nyirjesy P; Fox R; Sobel JD
Fertil Steril; 2011 Feb; 95(2):803.e1-2. PubMed ID: 20840882
[TBL] [Abstract][Full Text] [Related]
13. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
14. Recurrent vulvovaginal candidiasis.
Ringdahl EN
Mo Med; 2006; 103(2):165-8. PubMed ID: 16703718
[TBL] [Abstract][Full Text] [Related]
15. Community-acquired fungemia due to a multiple-azole-resistant strain of Candida tropicalis.
Jandourek A; Brown P; Vazquez JA
Clin Infect Dis; 1999 Dec; 29(6):1583-4. PubMed ID: 10585825
[No Abstract] [Full Text] [Related]
16. Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis.
Vazquez JA; Peng G; Sobel JD; Steele-Moore L; Schuman P; Holloway W; Neaton JD
Clin Infect Dis; 2001 Oct; 33(7):1069-75. PubMed ID: 11528582
[TBL] [Abstract][Full Text] [Related]
17. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
[TBL] [Abstract][Full Text] [Related]
18. Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital.
Capoor MR; Nair D; Deb M; Verma PK; Srivastava L; Aggarwal P
Jpn J Infect Dis; 2005 Dec; 58(6):344-8. PubMed ID: 16377864
[TBL] [Abstract][Full Text] [Related]
19. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
Mann PA; McNicholas PM; Chau AS; Patel R; Mendrick C; Ullmann AJ; Cornely OA; Patino H; Black TA
Antimicrob Agents Chemother; 2009 Dec; 53(12):5026-34. PubMed ID: 19786600
[TBL] [Abstract][Full Text] [Related]
20. Antifungal susceptibility testing of micafungin against Candida glabrata isolates.
Oliveira ER; Fothergill A; Kirkpatrick WR; Patterson TF; Redding SW
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Apr; 105(4):457-9. PubMed ID: 18329581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
